Table of Contents
After Bluebird Bio (BLUE) announced plans this week to end commercial operations in Europe, the move is raising fresh questions about the extent to which selling such pricey treatments is viable for small biotechs in one of the world’s biggest markets.
In explaining the move, the biotech complained that it has become a losing proposition trying to convince European Union member states to make large upfront payments for therapies that can save health care systems much higher costs later. So instead, the company is shifting its focus to the U.S., where it is more likely to get reimbursed at the desired prices.
What is it?
STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis.
Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What’s included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.